ClinicalTrials.gg
RecruitingNCT07855419Updated Oct 7, 2026

Sarcopenia and Interlaminar Epidural Steroid Injection Outcomes in Lumbar Spinal Stenosis

An observational study in Spinal Stenosis Lumbar and Sarcopenia, sponsored by Marmara University. Recruiting at 1 site in Turkey (Türkiye). Open to participants aged 50 Years to 75 Years. Per ClinicalTrials.gov, last updated 2026-10-07.

Sponsored by Marmara University · Observational

How we know

From the registry’s dates

  • Started Oct 2026; still recruiting 1 month later.
Updated Oct 7, 2026Now RecruitingSite recruiting status changed+1 moreGo to Updates ↓

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Study type
Observational
Model
Cohort
Time perspective
Prospective
Enrollment
70
Ages
50 Years to 75 Years
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-22

Among 131 studies in Sarcopenia with a site in Turkey — 36 open to participants now, 43 under way, none of them phase 3. Sarcopenia · Turkey.

Planned enrollment
68th of 97
70 · median 100
Started
2026
with 26 others
Observational
97 of 131
30 open now
Primary completion
2027-03
later than 32 of 42 live
Registered
124th of 131
by date

Among the 131 studies in Sarcopenia with a site in Turkey, this one is the 68th largest by planned enrollment of the 97 observational ones that give a count, is one of 27 that started in 2026, is one of 97 observational ones, reaches primary completion later than 32 of the 42 other live ones, and was the 124th registered.

Sarcopenia

1,334 studies on the registry are indexed under Sarcopenia; 418 are open to participants now.

Browse Sarcopenia studies →

Open to participants now

36 of the 131 studies in Sarcopenia with a site in Turkey are open now. Recruiting first, the newest first:

30 more — sign in →

All 36 open studies →

A study can be open while its sites in Turkey have not opened yet or have stopped. Only those recruiting at a site in Turkey →

Who these studies take

Of the 246 Sarcopenia studies recruiting now, 155 (63%) set no upper age limit and 32 (13%) stop at 75 or younger; 9 take children under 18; 62 take healthy volunteers.

This study: 50 Years to 75 Years · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 131 studies in Sarcopenia with a site in Turkey, or all of them as a file.
02

Study summary

This prospective observational study aims to investigate the association between sarcopenia and clinical outcomes following interlaminar epidural steroid injection in patients with lumbar spinal stenosis.

Patients who are scheduled to undergo interlaminar epidural steroid injection as part of routine clinical care will be enrolled. Before the procedure, sarcopenia-related assessments, including the SARC-F questionnaire, handgrip strength, and the five-times sit-to-stand test, will be performed. Lumbar magnetic resonance imaging (MRI) will also be evaluated for paraspinal muscle characteristics and the severity of lumbar spinal stenosis.

Pain intensity, functional status, walking capacity, and health-related quality of life will be assessed at baseline. Pain intensity, functional status, and health-related quality of life will be reassessed at 3 weeks and 3 months after the procedure. The study will evaluate whether sarcopenia and MRI-based paraspinal muscle characteristics are associated with clinical outcomes following interlaminar epidural steroid injection.

03

Conditions studied

  • Spinal Stenosis Lumbar
  • Sarcopenia

Keywords

  • Sarcopenia
  • Epidural injection
  • Spinal stenosis
04

Who can participate

Ages eligible
50 Years to 75 Years
Sexes eligible
All
Accepts healthy volunteers
No
Sampling method
Non-probability sample

Study population

The study population will consist of patients aged 50-75 years with clinically and radiologically diagnosed lumbar spinal stenosis who are scheduled to undergo interlaminar epidural steroid injection as part of routine clinical care due to persistent symptoms despite conservative treatment. Participants will be classified according to sarcopenia status based on baseline assessments and followed for 3 months.

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Clinical and radiological diagnosis of lumbar spinal stenosis
  • Persistent symptoms despite conservative treatment and scheduled to undergo interlaminar epidural injection as part of routine clinical care
  • Age between 50 and 75 years
  • Low back and/or leg pain for at least 3 months
  • Availability of lumbar magnetic resonance imaging (MRI)

Exclusion criteria

Exclusion Criteria:

  • History of lumbar fusion surgery
  • Lumbar epidural injection within the previous 3 months
  • Prominent radiculopathy due to lumbar disc herniation
  • Severe motor deficit or an indication for surgical treatment
  • Polyneuropathy, neuromuscular disease, or neurological disease that may significantly affect muscle mass
  • Active or systemic inflammatory disease
  • Significant mobility limitation due to advanced hip or knee osteoarthritis
  • Cognitive impairment or communication problems that may prevent completion of study assessments
  • Coagulopathy or active infection constituting a to epidural injection
  • Inflammatory rheumatic disease requiring chronic corticosteroid therapy
Terms in these criteria, in plain language(3)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Corticosteroids (steroids)

Anti-inflammatory medicines such as prednisone, prednisolone and dexamethasone — not the anabolic steroids used for muscle.

Studies differ in what they allow: check which steroid medicines, routes (tablets, injections, creams, inhalers, eye drops) and doses this study accepts.

Cancer (malignancy)

Malignancy means cancer. Criteria about another or earlier malignancy ask whether you have had a different cancer, usually within a set number of years.

Some are commonly allowed, such as treated skin cancers other than melanoma and early cancers removed completely — check the exceptions this study lists.

Contraindication

A reason a treatment, test or procedure should not be given to a particular person, such as an allergy, another illness or a medicine they take.

05

Study design

Observational model
Cohort
Time perspective
Prospective
Enrollment
70 participants (estimated)
Patient registry
No

Groups and cohorts

  • Patients with Sarcopenia

    Patients with lumbar spinal stenosis who meet the European Working Group on Sarcopenia in Older People 2 (EWGSOP2) criteria for probable sarcopenia based on reduced muscle strength at baseline and who are scheduled to undergo interlaminar epidural steroid injection as part of routine clinical care.

  • Patients without Sarcopenia

    Patients with lumbar spinal stenosis who do not meet the European Working Group on Sarcopenia in Older People 2 (EWGSOP2) criteria for probable sarcopenia based on muscle strength assessment at baseline and who are scheduled to undergo interlaminar epidural steroid injection as part of routine clinical care.

06

What researchers measure

Primary outcomes

  1. Change in Leg Pain Following Interlaminar Epidural Steroid Injection by Sarcopenia Status

    Leg pain intensity will be assessed using the Numeric Rating Scale (NRS), ranging from 0 to 10, where 0 indicates no pain and 10 indicates the worst imaginable pain. NRS scores will be recorded at baseline, 3 weeks, and 3 months. Changes in leg pain intensity from baseline will be compared between patients with and without sarcopenia.

    Time frame: Baseline, 3 weeks, and 3 months

Secondary outcomes

  1. Change in Low Back Pain Following Interlaminar Epidural Steroid Injection by Sarcopenia Status

    Low back pain intensity will be assessed using the Numeric Rating Scale (NRS), ranging from 0 to 10, where 0 indicates no pain and 10 indicates the worst imaginable pain. NRS scores will be recorded at baseline, 3 weeks, and 3 months. Changes in low back pain intensity from baseline will be compared between patients with and without sarcopenia.

    Time frame: Baseline, 3 weeks, and 3 months

  2. Change in Functional Disability Following Interlaminar Epidural Steroid Injection by Sarcopenia Status

    Functional disability will be assessed using the Istanbul Low Back Pain Disability Index (ILBPDI). The ILBPDI consists of 18 items and has a total score ranging from 0 to 90, with higher scores indicating greater disability. ILBPDI scores will be recorded at baseline, 3 weeks, and 3 months. Changes from baseline will be compared between patients with and without sarcopenia.

    Time frame: Baseline, 3 weeks, and 3 months

  3. Change in Health-Related Quality of Life Following Interlaminar Epidural Steroid Injection by Sarcopenia Status

    Health-related quality of life will be assessed using the 12-Item Short Form Health Survey (SF-12), which provides Physical Component Summary (PCS) and Mental Component Summary (MCS) scores. Both scores range from 0 to 100, with higher scores indicating better health-related quality of life. Scores will be recorded at baseline, 3 weeks, and 3 months. Changes from baseline will be compared between patients with and without sarcopenia.

    Time frame: Baseline, 3 weeks, and 3 months

  4. Correlation Between Erector Spinae Cross-Sectional Area and Leg Pain Outcome

    Erector spinae cross-sectional area (CSA) will be measured on baseline lumbar magnetic resonance imaging (MRI) in square centimeters (cm²). Leg pain intensity will be assessed using the Numeric Rating Scale (NRS), ranging from 0 to 10, with higher scores indicating greater pain intensity. The correlation between baseline erector spinae CSA and change in leg pain NRS from baseline will be evaluated.

    Time frame: Baseline Magnetic Resonance Imaging; leg pain at baseline, 3 weeks and 3 months

07

Study locations

1 of 1 sites recruiting
08

References and documents

Individual participant data

Plan to share: No — Individual participant data are not planned to be shared publicly due to participant confidentiality and data protection considerations.

No publications or documents are linked to this record.

09

Timeline

2 registry updates since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Started Oct 2026 (actual). Primary completion is estimated for Mar 2027, 5 months after the start.

Of 192 non-industry observational studies under Sarcopenia, half reached primary completion within 26 months of starting (the median), counting those still running; a quarter within 12 and three quarters within 63. This study's planned 5 months is below that.

Counting every sponsor, half of 194 studies reached it within 26 months; a quarter within 12 and three quarters within 63.

How these figures are worked out, and which studies are left out of them.

Registered
Sep 28, 2026
First posted
Oct 2, 2026
StartActual
Oct 2, 2026
Primary completionEst.
Mar 2027
CompletionEst.
Apr 2027
Last update
Oct 7, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
Status
Not yet recruiting→Recruiting
changed Oct 7, 2026
Sites
Marmara University Pendik Training and Research Hospital is now Recruiting
Oct 7, 2026
Secondary outcomes
1 edited, 1 description edited
What changed in the outcomes
  • ChangedBefore Association Between MRI-Based Paraspinal Muscle Characteristics and Clinical OutcomesNow Correlation Between Erector Spinae Cross-Sectional Area and Leg Pain OutcomeTime frame: Baseline Magnetic Resonance Imaging; clinical outcomes at 3 weeks and 3 months → Baseline Magnetic Resonance Imaging; leg pain at baseline, 3 weeks and 3 months
  • DescriptionChange in Health-Related Quality of Life Following Interlaminar Epidural Steroid Injection by Sarcopenia Status: how it is measured was reworded
Oct 7, 2026
Registered
First appeared on the registry
Oct 2, 2026
Show all 2 updates
  1. Oct 7, 2026
    Not yet recruiting→Recruiting
    Marmara University Pendik Training and Research Hospital is now Recruiting
    Secondary outcomes 1 edited, 1 description edited
    What changed in the outcomes
    • ChangedBefore Association Between MRI-Based Paraspinal Muscle Characteristics and Clinical OutcomesNow Correlation Between Erector Spinae Cross-Sectional Area and Leg Pain OutcomeTime frame: Baseline Magnetic Resonance Imaging; clinical outcomes at 3 weeks and 3 months → Baseline Magnetic Resonance Imaging; leg pain at baseline, 3 weeks and 3 months
    • DescriptionChange in Health-Related Quality of Life Following Interlaminar Epidural Steroid Injection by Sarcopenia Status: how it is measured was reworded
    + 2 other changes: verification date and date precision
  2. Oct 2, 2026
    First appeared on the registry

From the registry record's own update history. This site started tracking changes on Sep 25, 2026; for anything earlier, see the record history on ClinicalTrials.gov ↗

10

Registry details

Key details

Study ID
NCT07855419
Lead sponsor
Marmara University
Responsible party
Sponsor
First posted
Oct 2, 2026
Start date
Oct 2, 2026
Primary completion
Mar 2027 (estimated)
Completion
Apr 2027 (estimated)
Last update
Oct 7, 2026

Study contacts

Konuralp Karbeyaz
Contact
nurbanuhindioglu@gmail.com
+90 216 625 45 45

Oversight

Data monitoring committee
No
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Interested in this study?

Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.

Contact study team

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion